Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AMM:DADI's 5-Year Yield-on-Cost % is ranked better than 52.53% of 514
companies
in the Drug Manufacturers industry
Industry Median: 2.325
vs AMM:DADI: 2.63
Dar Al Dawa Development and Investment (AMM:DADI) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Dar Al Dawa Development and Investment 5-Year Yield-on-Cost % Related Terms
AMM:DADI vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dar Al Dawa Development and Investment's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dar Al Dawa Development and Investment 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dar Al Dawa Development and Investment's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Dar Al Dawa Development and Investment's 5-Year Yield-on-Cost % falls into.
Dar Al Dawa Development and Investment 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Dar Al Dawa Development and Investment (AMM:DADI) has a 5-Year Yield-on-Cost % of 2.63 as of Jul. 18, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Dar Al Dawa Development and Investment and its competitors. This is 43% below median its historical median of 4.60. Over the past decade, Dar Al Dawa Development and Investment's 5-Year Yield-on-Cost % has ranged from 2.63 to 7.60. According to the industry distribution chart, Dar Al Dawa Development and Investment ranks #244 out of 514 companies in the Drug Manufacturers industry, placing it in the top 47.5%.
Is Dar Al Dawa Development and Investment's 5-Year Yield-on-Cost % too high?
Dar Al Dawa Development and Investment's current 5-Year Yield-on-Cost % of 2.63 is 43% below median its 10-year median of 4.60. Over the past 10 years, this metric has ranged from a low of 2.63 to a high of 7.60. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.33. Dar Al Dawa Development and Investment's value of 2.63 is 13.1% above this industry median. Based on the distribution chart, Dar Al Dawa Development and Investment ranks #244 out of 514 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Dar Al Dawa Development and Investment has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dar Al Dawa Development and Investment's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dar Al Dawa Development and Investment ranks #244 out of 514 companies for 5-Year Yield-on-Cost %. This puts Dar Al Dawa Development and Investment in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.33. Dar Al Dawa Development and Investment's value of 2.63 is 13.1% above this benchmark. Historically, Dar Al Dawa Development and Investment's own 5-Year Yield-on-Cost % has ranged from 2.63 to 7.60 over the past decade. While the company's 10-year median is 4.60 vs. the industry median of 2.33, Dar Al Dawa Development and Investment has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.33, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dar Al Dawa Development and Investment's current 5-Year Yield-on-Cost % of 2.63 is 13.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Dar Al Dawa Development and Investment and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dar Al Dawa Development and Investment's current 5-Year Yield-on-Cost % is 2.63, which is 43% below median its own 10-year median of 4.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dar Al Dawa Development and Investment stock overvalued right now?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment (AMM:DADI) is currently considered Fairly Valued. The stock's GF Value™ is JOD1.10, compared to a current price of JOD1.14 — trading 3.6% above its estimated fair value. The current 5-Year Yield-on-Cost % is 2.63, which is 43% below median its 10-year median of 4.60 and 13.1% above the Drug Manufacturers industry median of 2.33. Dar Al Dawa Development and Investment's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Dar Al Dawa Development and Investment (AMM:DADI), the current 5-Year Yield-on-Cost % is 2.63 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dar Al Dawa Development and Investment (AMM:DADI) Overvalued in 2026?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment stock appears to be overvalued.
The current stock price of JOD1.14 is trading 3.6% above its estimated GF Value™ of JOD1.10.
GuruFocus considers Dar Al Dawa Development and Investment to be Fairly Valued.
Key valuation signals for AMM:DADI:
5-Year Yield-on-Cost %: 2.63 (43% below median its 10-year median of 4.60)
GF Value™: JOD1.10 vs. price of JOD1.14 (3.6% above fair value)
Industry Position: 13.1% above the Drug Manufacturers median (#244 of 514)
No single metric tells the full story. See the AMM:DADI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dar Al Dawa Development and Investment Business Description
Dar Al Dawa Development and Investment is a pharmaceutical company. The main objectives are the production of medical, chemical, and pharmaceutical products, and importing pharmaceutical products. The subsidiaries' main objectives are marketing and distributing the Company's products, producing some specialized medical products, and investment activities. It offers products in the therapeutic areas of anti-infective, cardiovascular, diabetes, dermatology, eye-ear preparations, gastroenterology and metabolism, genitourinary system and sex hormones, musculoskeletal system, nervous system, ophthalmological/otological, and respiratory system, as well as vitamins. The company's geographical segments are Levant and Iraq, Gulf and Yemen, Africa, and Europe and Asia.
78GF Score
Get the complete analysis for AMM:DADI
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMM:DADI has been successfully added to your 
